Glibenclamide & Metformin Hydrochloride SR Tablets
Each sustained-release tablet contains Glibenclamide 5 mg + Metformin Hydrochloride 500 mg; excipients q.s.
Related Glibenclamide-only presentations: IP 5 mg, BP 5 mg (Gilben; Trippleace Glibenclamide-5), each uncoated.
Usage: Along with diet and exercise to improve blood glucose control in selected adults with type 2 diabetes.
Category: Anti Diabetic Drugs
Therapeutic Category: Anti Diabetic
SKU: Glibenclamide & Metformin HCl SR Tablets
Categories: Contract Manufacturer, Formulations Exporter India, Manufacturing Pharmaceutical Company India, Pharmaceutical Exporter India, Pharmaceutical Formulations India, Tablets Manufacturer, WHO GMP Certified Formulations
Glibenclamide & Metformin HCl SR Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
Healthy Life Pharma Pvt. Ltd. lists Glibenclamide & Metformin Hydrochloride SR Tablets for the management of type 2 diabetes when prescribed alongside diet and exercise. The supplied fixed-dose combination contains glibenclamide 5 mg and metformin hydrochloride 500 mg in a sustained-release tablet. Separate glibenclamide-only 5 mg tablets (IP and BP) are also listed and must not be confused with the combination.
| Product / Brand | Composition per Tablet | Dosage Form | Standard |
|---|---|---|---|
| Glibenclamide + Metformin HCl SR | Glibenclamide 5 mg + Metformin Hydrochloride 500 mg | Sustained-release tablet | Combination; standard not specified |
| Glibenclamide IP 5 mg | Glibenclamide IP 5 mg; excipients q.s. | Uncoated tablet | IP |
| Gilben | Glibenclamide BP 5 mg | Uncoated tablet | BP |
| Trippleace Glibenclamide-5 | Glibenclamide BP 5 mg | Uncoated tablet | BP |
The 2.5 mg / 500 mg combination is mentioned in the description but no composition was supplied for it. Availability and registration require confirmation.
Modified-release tablets require formulation-specific controls for uniform distribution of low-dose glibenclamide and the intended metformin release profile. Matrix or multilayer technologies are possible approaches, but the exact process, release duration and whether both ingredients are modified-release must be verified from the approved product specification. Moisture-protective packaging may be selected according to stability data.
Quality testing may include identity, assay and uniformity of both active ingredients, impurities, tablet integrity, and multipoint dissolution testing for the modified-release component. Acceptance criteria, stability and shelf life depend on the registered product.
Glibenclamide (glyburide) is a sulfonylurea that increases pancreatic insulin secretion and can cause significant hypoglycaemia. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity. This combination may be considered for selected adults with type 2 diabetes when individualised therapy is appropriate. Glibenclamide carries a relatively high risk of prolonged hypoglycaemia, particularly in older adults and people with renal impairment; alternative treatments may be preferred under current clinical guidance.
Product-specific regulatory dossiers, certificates of analysis and applicable export documents may be provided subject to availability. Local registration requirements and the approved modified-release specifications must be confirmed before supply.
Who manufactures these tablets?
Healthy Life Pharma Pvt. Ltd., India.
Are glibenclamide-only tablets the same as the combination?
No. The combination additionally contains metformin hydrochloride 500 mg.
Can this cause low blood sugar?
Yes. Glibenclamide can cause serious or prolonged hypoglycaemia. Patients should know the symptoms and follow their diabetes care plan.
What does SR mean?
Sustained release indicates a designed release profile, but the exact release characteristics must be confirmed for the registered product.
Use only as prescribed after assessment of blood glucose, kidney function, diet, concomitant medicines and hypoglycaemia risk. Follow the approved label for administration with meals. Do not crush or chew sustained-release tablets unless the specific product instructions permit it. The 2.5 mg/500 mg and 5 mg/500 mg strengths are not interchangeable.
Store under conditions stated on the approved product label, protected from excessive moisture and heat. Keep out of reach of children.